Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(50.0%)
Phase 2
1(50.0%)
2Total
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03795909Phase 1Unknown

Ruxolitinib Combined With Dexamethasone for HLH

Role: lead

NCT03687463Unknown

Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia

Role: lead

NCT03654703Phase 2Unknown

Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML

Role: lead

NCT03198195Unknown

Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome

Role: lead

All 4 trials loaded